Tamoxifen: A personal retrospective

V. Craig Jordan

doi:10.1016/S1470-2045(00)00009-7

Tamoxifen: A personal retrospective

V. Craig Jordan

Research output: Contribution to journal › Comment/debate › peer-review

40 Scopus citations

Abstract

Tamoxifen, originally described as an anti-oestrogen and antifertility agent in the rat, is now a pioneering medicine for the treatment and prevention of breast cancer. Its success is the result of an effective collaboration between laboratory research and clinical trial processes. However, this drug is more than just an anti-oestrogen to treat breast cancer. Laboratory and clinical research defined the concept of selective oestrogen receptor modulation in the 1980s. Non-steroidal anti-oestrogens show oestrogen-like activity in bones and lower cholesterol, but block oestrogen action in the breast and uterus. This realisation led to the development of chemical cousins, known as selective oestrogen receptor modulators. One of these compounds, raloxifene, is used for the prevention of osteoporosis, but is currently being tested as a preventive for breast cancer.

Original language	English (US)
Pages (from-to)	43-49
Number of pages	7
Journal	Lancet Oncology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(00)00009-7
State	Published - Sep 1 2000
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(00)00009-7

Cite this

@article{0e4bdc1549904d7888b4e03e8888c233,

title = "Tamoxifen: A personal retrospective",

abstract = "Tamoxifen, originally described as an anti-oestrogen and antifertility agent in the rat, is now a pioneering medicine for the treatment and prevention of breast cancer. Its success is the result of an effective collaboration between laboratory research and clinical trial processes. However, this drug is more than just an anti-oestrogen to treat breast cancer. Laboratory and clinical research defined the concept of selective oestrogen receptor modulation in the 1980s. Non-steroidal anti-oestrogens show oestrogen-like activity in bones and lower cholesterol, but block oestrogen action in the breast and uterus. This realisation led to the development of chemical cousins, known as selective oestrogen receptor modulators. One of these compounds, raloxifene, is used for the prevention of osteoporosis, but is currently being tested as a preventive for breast cancer.",

author = "Jordan, {V. Craig}",

note = "Funding Information: Thanks are due to the Medical Research Council, who awarded me the last PhD scholarship for 1969. This history is dedicated to Edward R Clark at the University of Leeds, who, in 1969, suggested my thesis topic of oestrogen receptors and anti-oestrogens. The writing of this paper was funded, in part, by the Lynn Sage Breast Cancer Research Foundation at Northwestern Memorial Hospital, Chicago, and the Avon Breast Cancer Research Fund.",

year = "2000",

month = sep,

day = "1",

doi = "10.1016/S1470-2045(00)00009-7",

language = "English (US)",

volume = "1",

pages = "43--49",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Tamoxifen

T2 - A personal retrospective

AU - Jordan, V. Craig

N1 - Funding Information: Thanks are due to the Medical Research Council, who awarded me the last PhD scholarship for 1969. This history is dedicated to Edward R Clark at the University of Leeds, who, in 1969, suggested my thesis topic of oestrogen receptors and anti-oestrogens. The writing of this paper was funded, in part, by the Lynn Sage Breast Cancer Research Foundation at Northwestern Memorial Hospital, Chicago, and the Avon Breast Cancer Research Fund.

PY - 2000/9/1

Y1 - 2000/9/1

N2 - Tamoxifen, originally described as an anti-oestrogen and antifertility agent in the rat, is now a pioneering medicine for the treatment and prevention of breast cancer. Its success is the result of an effective collaboration between laboratory research and clinical trial processes. However, this drug is more than just an anti-oestrogen to treat breast cancer. Laboratory and clinical research defined the concept of selective oestrogen receptor modulation in the 1980s. Non-steroidal anti-oestrogens show oestrogen-like activity in bones and lower cholesterol, but block oestrogen action in the breast and uterus. This realisation led to the development of chemical cousins, known as selective oestrogen receptor modulators. One of these compounds, raloxifene, is used for the prevention of osteoporosis, but is currently being tested as a preventive for breast cancer.

AB - Tamoxifen, originally described as an anti-oestrogen and antifertility agent in the rat, is now a pioneering medicine for the treatment and prevention of breast cancer. Its success is the result of an effective collaboration between laboratory research and clinical trial processes. However, this drug is more than just an anti-oestrogen to treat breast cancer. Laboratory and clinical research defined the concept of selective oestrogen receptor modulation in the 1980s. Non-steroidal anti-oestrogens show oestrogen-like activity in bones and lower cholesterol, but block oestrogen action in the breast and uterus. This realisation led to the development of chemical cousins, known as selective oestrogen receptor modulators. One of these compounds, raloxifene, is used for the prevention of osteoporosis, but is currently being tested as a preventive for breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034286302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034286302&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(00)00009-7

DO - 10.1016/S1470-2045(00)00009-7

M3 - Comment/debate

C2 - 11905688

AN - SCOPUS:0034286302

SN - 1470-2045

VL - 1

SP - 43

EP - 49

JO - Lancet Oncology

JF - Lancet Oncology

IS - 1

ER -

Tamoxifen: A personal retrospective

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this